Dianthus Therapeutics Announces Inducement Grants
Dianthus Therapeutics, a Nasdaq-listed biotech company, has announced the issuance of inducement grants in the form of stock options to new employees. This move, common in the biotech industry, aims to attract and retain top talent to support the company's drug development pipeline and future growth. The grants were issued under Nasdaq Listing Rule 5635(c)(4) to offer competitive compensation packages to skilled professionals.
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics, a clinical-stage biotechnology company, announced it granted inducement equity awards to eight new non-executive employees on April 1, 2026. These grants, approved by the Compensation Committee, consisted of non-qualified stock options for 135,000 shares of common stock with an exercise price of $84.56 per share, vesting over four years. This action is in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment.
Dianthus gives 8 new employees stock options at $84.56 a share
Dianthus Therapeutics (Nasdaq: DNTH) announced that it granted inducement equity awards to eight new non-executive employees on April 1, 2026. These awards consist of non-qualified stock options for an aggregate of 135,000 shares, with an exercise price of $84.56 per share and a 10-year term. The options will vest 25% after one year, then monthly over the subsequent 36 months, and were approved by the independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Dianthus Therapeutics CFO Sells $9.5 Million in Stock
Ryan Savitz, CFO of Dianthus Therapeutics, sold 114,367 shares of common stock worth approximately $9.49 million on March 31, 2026, after exercising stock options. This sale represented 100% of his direct common stock holdings, though he retains 90,399 stock options. The transaction, executed under a prearranged Rule 10b5-1 plan, is considered a strategy to lock in gains after the company's stock rose 400% over the past year, rather than a lack of confidence in the company, which is advancing its lead candidate, DNTH103, into Phase 3 trials.
Dianthus Therapeutics CFO Sells $9.5 Million in Stock
Dianthus Therapeutics' CFO, Ryan Savitz, sold 114,367 shares of common stock worth approximately $9.49 million on March 31, 2026. This transaction was an exercise of stock options, immediately sold in the open market, and was conducted under a prearranged Rule 10b5-1 plan. Despite the sale, Savitz retains 90,399 stock options, indicating continued equity participation, and the company's lead candidate, DNTH103, is progressing towards Phase 3 trials.
A Look At Dianthus Therapeutics (DNTH) Valuation After A Strong Year Of Share Price Gains
Dianthus Therapeutics (DNTH) has seen significant share price gains over the past year, with a 55% increase in the last month, yet it trades at a high price-to-book (P/B) ratio of 9.2x. This P/B is considered overvalued compared to its industry and peers, suggesting that future expectations are already priced in. Investors are advised to consider clinical and regulatory risks and the company's ongoing losses before making investment decisions.
Dianthus Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
This article is a notice of the proposed sale of securities by Dianthus Therapeutics, filed pursuant to Rule 144. It is a mandatory disclosure related to the sale of restricted and control securities.
Dianthus Therapeutics EVP Sells Over $9 Million in Shares
Ryan Savitz, EVP of Dianthus Therapeutics (NASDAQ:DNTH), sold 114,367 shares for approximately $9.49 million on March 31st. This insider sale raises concerns about the biotech firm's financial outlook, especially after it recently reported wider-than-expected losses and despite a significant surge in its stock price over the past year. Investors are advised to monitor the company's future earnings and pipeline updates closely.
Dianthus therapeutics director Soteropoulos sells $47985 in stock
Dianthus Therapeutics director Paula Soteropoulos sold 599 shares of common stock for over $47,000 and exercised options for 599 shares on March 31, 2026. This transaction was part of a pre-arranged trading plan. The company recently completed a public offering raising $719 million and received positive analyst ratings following FDA updates for its clinical trials.
Savitz of Dianthus sold $9.5m in DNTH stock
Ryan Savitz, EVP, CFO & CBO of Dianthus Therapeutics, Inc., sold $9.5 million in company stock on March 31, 2026, as part of a pre-arranged trading plan. Concurrently, he exercised options to acquire 114,367 shares. This news follows Dianthus Therapeutics' recent $719 million public offering and positive analyst ratings from William Blair and Wells Fargo, prompted by FDA updates and promising clinical trial results for claseprubart.
Dianthus Therapeutics (DNTH) CFO exercises options, sells 114,367 shares
Dianthus Therapeutics EVP, CFO & CBO Ryan Savitz exercised stock options to acquire 114,367 shares of common stock, with exercise prices of $8.44 and $17.88 per share, on March 31, 2026. He subsequently sold all 114,367 shares in open-market transactions at weighted average prices ranging from $78.33 to $85.54 per share, as part of a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Savitz directly owns no shares of common stock.
Dianthus Therapeutics (DNTH) director exercises options then sells 599 shares
Dianthus Therapeutics director Paula Soteropoulos exercised stock options for 599 shares of common stock at $8.44 per share on March 31, 2026. She immediately sold all 599 shares at $80.11 per share under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following the transaction, her direct holdings from this specific event show 0 common shares.
Dianthus Therapeutics stock hits 52-week high at 88.35 USD
Dianthus Therapeutics (DNTH) stock has reached a new 52-week high of $88.35, currently trading at $87.83 with a market capitalization of $4.66 billion. This surge reflects a 399% increase over the last year and a 116% gain in six months, though InvestingPro suggests it may be overbought and overvalued. The company recently completed a public offering raising $719 million and received positive analyst ratings following FDA updates and promising clinical trial results.
Strength Observed in Dianthus Therapeutics, Inc. (DNTH): Will Its 5.6% Increase Lead to Further Gains?
Dianthus Therapeutics (DNTH) saw a 5.6% stock increase due to optimistic sentiment surrounding its drug pipeline, specifically an early "GO" decision and FDA approval for modifications to the CAPTIVATE trial for its drug claseprubart. Despite these gains, the company faces projected quarterly losses and a significant drop in revenue, with downward revisions in EPS estimates that typically do not lead to sustained price increases. Investors are advised to monitor if the recent rally can be maintained, as the stock currently holds a Zacks Rank #3 (Hold).
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing
Dianthus Therapeutics, Inc. (DNTH) has filed a Form 144 with the SEC, indicating a proposed sale of securities. The filing details the sale of 114,367 shares of common stock by an individual through Morgan Stanley Smith Barney LLC, acquired on March 31, 2026, via the exercise of stock options. This neutral filing suggests a routine transaction with no reported material adverse information from the seller.
DNTH insider sells 27,594 shares via 10b5-1; plans 1,198-share option sale (DNTH)
An insider at Dianthus Therapeutics (DNTH) has reported a planned sale of 1,198 shares of common stock on March 31, 2026, stemming from the exercise of stock options. Additionally, the filing discloses recent 10b5-1 sales completed on March 24, 2026, totaling 27,594 shares, which generated aggregate proceeds of $2,153,579.25. These transactions are routine compliance filings for insider dispositions.
Dianthus Therapeutics (DNTH) Receives a Buy from Wells Fargo
Wells Fargo analyst Sadia Rahman maintained a Buy rating on Dianthus Therapeutics with a $135.00 price target. This follows a similar Buy rating from LifeSci Capital's Rami Katkhuda, while TipRanks – xAI reiterated a Hold rating. The report highlights Dianthus Therapeutics' recent financial performance, including a quarterly revenue of $284 thousand and a net profit of $97.91 million.
Director at Dianthus Therapeutics (DNTH) exercises options and sells shares
Dianthus Therapeutics director Paula Soteropoulos exercised stock options for 27,594 shares at $8.44 per share and immediately sold them at $78.05 per share. These transactions, conducted under a pre-arranged Rule 10b5-1 trading plan, resulted in her holding no direct shares of the common stock post-sale. The Form 4 filing details these transactions and confirms the director's current direct share ownership is zero.
Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 5.6% - Time to Buy?
Dianthus Therapeutics (NASDAQ:DNTH) saw its shares rise by 5.6% on Thursday, closing at $84.05 with trading volume significantly below average. Despite largely positive analyst ratings and an average price target of $117.30, the clinical-stage biotech company faces challenges with missed EPS estimates, minimal revenue, negative margins, and recent insider stock sales totaling $16.3 million. The article provides an overview of recent analyst activities, financial performance, and insider/institutional transactions.
According to a public SEC filing, biopharmaceutical company Dianthus Therapeutics Inc. (DNTH) is adjusting the enrollment criteria for the clinical trial of its core drug Claseprubart.
Dianthus Therapeutics Inc. (DNTH) is modifying the enrollment criteria for the clinical trial of its primary drug, Claseprubart, as detailed in a recent SEC filing. The biopharmaceutical company plans to submit these proposed amendments to the U.S. Food and Drug Administration in the first quarter of 2026 for formal review. This adjustment indicates a strategic change in the drug's development pathway.
FDA backs Dianthus (NASDAQ: DNTH) lupus risk update as cash runway extends to 2030
Dianthus Therapeutics received written FDA agreement in March 2026 to modify screening criteria and the classification of lupus risk across all claseprubart clinical trials. This change, which removes anti-nuclear antibody (ANA)-based screening and reclassifies hypothetical lupus risk to drug-induced lupus, is based on no reported cases of Systemic Lupus Erythematosus (SLE) or Drug-Induced Lupus (DIL) in any trial to date. The company also announced a strong financial position with approximately $1.2 billion in cash, extending its operational runway into 2030 to support multiple planned milestones for its autoimmune pipeline therapies, claseprubart and DNTH212.
Dianthus Therapeutics, Inc. (DNTH) Files Form 144
Dianthus Therapeutics, Inc. (DNTH) has filed a Form 144 with the SEC, indicating a proposed sale of securities under Rule 144 of the Securities Act of 1933. The filing details the sale of 27,594 shares of common stock with an aggregate market value of $2,188,756.08, acquired through the exercise of stock options on March 24, 2026. The sale is set to occur on NASDAQ on March 24, 2026, handled by Morgan Stanley Smith Barney LLC.
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Dianthus Therapeutics (NASDAQ:DNTH) has received a consensus "Moderate Buy" rating from thirteen research firms, with an average 12-month price target of $117.30. Despite a recent earnings miss, negative margins, and significant insider selling, several analysts have raised their price targets for the stock. Institutional investors have also been adjusting their stakes in the clinical-stage biotechnology company.
Dianthus Therapeutics, Inc. (DNTH) reports Q4 loss, misses revenue estimates
Dianthus Therapeutics, Inc. (DNTH) reported a loss for the fourth quarter, failing to meet revenue expectations. The company's financial performance fell short of analyst estimates.
Dianthus Therapeutics, Inc. (DNTH) stock jumps 12.0%: Will it continue to soar?
Dianthus Therapeutics, Inc. (DNTH) stock recently jumped 12.0%. This article poses the question of whether this upward trend will continue for the company's shares.
Assessing Dianthus Therapeutics (DNTH) Valuation After CAPTIVATE Milestone And Upsized Equity Offering
Dianthus Therapeutics (DNTH) has seen significant momentum after announcing an early interim response milestone in its Phase 3 CAPTIVATE trial for CIDP and following up with an upsized equity offering. The company’s stock has surged, with a 291.39% year-over-year return, leading to a high Price-to-Book ratio of 8.6x compared to peers and the broader biotech industry. Despite the trial success and market optimism, concerns remain regarding its reliance on a single lead asset, ongoing financial losses of US$162.337 million, and a rich valuation of US$4.2 billion.
Wells Fargo & Company Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH)
Wells Fargo & Company has initiated coverage on Dianthus Therapeutics (NASDAQ:DNTH) with an "Overweight" rating and a $135 price target, suggesting a 71% upside. This follows a "Moderate Buy" consensus from other analysts with a $117.30 target, despite the company reporting a quarterly EPS miss and significant insider selling. Dianthus Therapeutics focuses on developing complement therapeutics for autoimmune and inflammatory diseases, with its lead candidate DNTH103 currently in Phase 2 trials.
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
5AM Venture Management fully exited its position in Dianthus Therapeutics, selling 365,053 shares for $14.36 million in Q4, according to an SEC filing dated February 17, 2026. This exit occurred before a significant portion of Dianthus's 288% stock surge over the past year, much of which happened recently after a major capital raise. Despite the stock jump, Dianthus Therapeutics, a clinical-stage biotech company developing monoclonal antibody therapies, still has no approved products, and its valuation is driven by expectations rather than execution.
Boothbay Fund Management LLC Buys Shares of 138,963 Dianthus Therapeutics, Inc. $DNTH
Boothbay Fund Management LLC has acquired 138,963 shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) valued at approximately $5.47 million, establishing a new position in the company. Other institutional investors like Wellington Management Group and Vestal Point Capital also significantly increased their stakes, bringing total institutional ownership to about 47.53%. The purchases follow Dianthus Therapeutics' positive clinical news, an upsized underwritten offering that raised $719M, and several analyst upgrades, contrasting with some insider selling and a recent EPS miss.
[Form 4] Dianthus Therapeutics, Inc. /DE/ Insider Trading Activity
Dianthus Therapeutics, Inc.'s CEO and President, Marino Garcia, exercised stock options on March 16, 2026, acquiring 65,292 shares of common stock at exercise prices of $6.70 and $17.88. Following these transactions, Garcia Marino directly holds 65,292 common shares, with additional option awards vesting over time. This activity was reported in a Form 4 SEC filing, indicating the CEO's increased direct ownership in the company.
William Blair Maintains Outperform on Dianthus Therapeutics (DNTH) March 2026
William Blair has reiterated its Outperform rating on Dianthus Therapeutics (DNTH) as of March 16, 2026, signaling continued confidence in the company's development pipeline and commercial prospects without issuing a new price target. This recommitment comes after Dianthus priced an upsized offering, raising approximately $625 million. Meyka AI rates DNTH with a B+ grade, highlighting important catalysts like planned clinical readouts and regulatory interactions.
HighVista Strategies LLC Buys 38,364 Shares of Dianthus Therapeutics, Inc. $DNTH
HighVista Strategies LLC significantly increased its stake in Dianthus Therapeutics (NASDAQ:DNTH) by 241.9%, purchasing an additional 38,364 shares during the third quarter, bringing their total to 54,225 shares valued at $2.13 million. The article also details other institutional investor activities, recent analyst ratings which show a "Moderate Buy" consensus, and insider stock sales. Dianthus Therapeutics recently held an upsized public offering of $719 million and announced an early Phase 3 clinical trial decision, positively impacting investor sentiment despite a recent EPS miss.
HighVista Strategies Boosts Stake in Dianthus Therapeutics
HighVista Strategies LLC significantly increased its stake in Dianthus Therapeutics by 241.9% in the third quarter of 2026, bringing its total to 54,225 shares valued at $2.13 million. This increased investment suggests HighVista Strategies sees substantial potential in Dianthus Therapeutics' pipeline and future prospects, signaling growing confidence in the biotech firm's ability to advance its clinical programs. The firm cited Dianthus Therapeutics' promising drug candidates and market opportunities as key factors for this increased position.
Dianthus Therapeutics (DNTH) Is Up 19.4% After Early CAPTIVATE GO Decision And $719M Raise
Dianthus Therapeutics saw its stock rise 19.4% after reporting an early GO decision in its Phase 3 CAPTIVATE trial for CIDP, driven by achieving 20 confirmed responders and a favorable safety profile. Following this positive clinical news, the company successfully raised approximately $719 million through a public equity offering, extending its cash runway for ongoing trials, commercial readiness, and broader development of its neuromuscular franchise. While the early clinical data and significant capital raise strengthen the investment narrative, the article notes that investors must weigh the potential for future losses, dilution, and execution risks against the drug's anticipated commercial success.
Braidwell LP Purchases Shares of 835,057 Dianthus Therapeutics, Inc. $DNTH
Braidwell LP has acquired 835,057 shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) valued at approximately $32.86 million, representing 1.95% of the company. This comes amidst significant institutional buying, an upsized underwritten offering that raised $719M, and an early Phase-3 "go" decision which led to analyst upgrades and a stock rally. Despite this positive news, Dianthus Therapeutics remains a pre-profit company with negative earnings and margins, and insiders have recently sold a substantial number of shares.
Assessing Dianthus Therapeutics (DNTH) Valuation After Early CAPTIVATE GO Decision And Premium P/B Multiple
Dianthus Therapeutics (DNTH) received an early "GO" decision for its pivotal Phase 3 CAPTIVATE trial, leading to a significant rally in its share price. Despite this positive development and strong analyst targets, the company trades at a premium Price-to-Book ratio of 8.4x, much higher than industry and peer averages. This valuation suggests high investor expectations for its pipeline and future revenue, even as the company continues to incur losses and is not expected to be profitable in the next three years.
Integral Health Asset Management LLC Buys New Stake in Dianthus Therapeutics, Inc. $DNTH
Integral Health Asset Management LLC has acquired a new stake of 150,000 shares in Dianthus Therapeutics, Inc. (NASDAQ:DNTH), valued at approximately $5.9 million. This investment follows Dianthus's positive Phase 3 "go" decision and a successful $719 million offering, which led to a stock rally and analyst upgrades. Despite positive market reactions and institutional interest, insiders have recently sold over $16 million in shares, and the company remains a pre-profit, high-burn biotech, as highlighted by a recent EPS miss.
Integral Health Asset Management Acquires 150,000 Shares in Dianthus Therapeutics
Integral Health Asset Management LLC has acquired a new stake of 150,000 shares, valued at approximately $5.9 million, in Dianthus Therapeutics Inc. This investment signals strong investor confidence in Dianthus Therapeutics, a clinical-stage biotech company focusing on complement therapeutics for severe autoimmune and inflammatory diseases. The company is currently advancing its lead candidate, DNTH103, through Phase 2 clinical trials.
Dianthus therapeutics CAO sells shares for $3.56 million
Edward Carr, Chief Accounting Officer of Dianthus Therapeutics, Inc. (NASDAQ:DNTH), sold 43,682 shares for $3.56 million on March 12, 2026, while also exercising options to acquire an equal number of shares. This comes amidst a significant surge in DNTH shares and recent public offerings by the company aimed at funding clinical development. Analysts from Raymond James and Clear Street have upgraded their ratings and price targets for Dianthus, citing positive trial results.
Assessing Dianthus Therapeutics (DNTH) Valuation After Early CAPTIVATE GO Decision And Premium P/B Multiple
Dianthus Therapeutics (DNTH) recently received an early "GO" decision for its pivotal Phase 3 CAPTIVATE trial, leading to significant stock price increases. Despite this momentum and positive analyst forecasts, the company trades at a high Price-to-Book ratio of 8.4x compared to industry averages, raising questions about whether its valuation is justified given ongoing losses and limited current revenue. Investors are clearly valuing DNTH's future pipeline and potential rather than current financial performance, indicating higher expectations than sector peers.
Dianthus (NASDAQ: DNTH) EVP sells 33,830 shares after option exercise
Dianthus Therapeutics' EVP and Head of R&D, Simrat Randhawa, exercised stock options for 33,830 shares and simultaneously sold all 33,830 shares in an open-market transaction. The sale, executed at $81.48 per share, was conducted under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Randhawa directly holds no common stock in the company.
Dianthus (NASDAQ: DNTH) raises $673.5M in stock and warrant deal
Dianthus Therapeutics, Inc. has successfully raised approximately $673.5 million through an underwritten public offering of common stock and pre-funded warrants. The offering included the sale of 7,313,582 shares of common stock at $81.00 per share and pre-funded warrants for 402,468 shares at $80.999 per warrant, with underwriters fully exercising an option for additional shares. This significant equity financing materially boosts the company's cash resources, with the net proceeds expected to be used for clinical programs, operations, or other corporate purposes.
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Dianthus Therapeutics, Inc. (Nasdaq: DNTH) has announced the closing of its upsized underwritten public offering, generating approximately $719 million in aggregate gross proceeds. The offering included the full exercise of the underwriters' option to purchase additional shares, totaling 8,470,989 shares of common stock and pre-funded warrants. The company plans to use the net proceeds to advance its clinical and preclinical development activities, commercial readiness, and for general corporate purposes.
Biotech Dianthus raises $719M to push autoimmune disease drugs
Dianthus Therapeutics (Nasdaq: DNTH) successfully closed an upsized underwritten public offering, raising approximately $719 million in gross proceeds. The offering included 8,470,989 common shares and 402,468 pre-funded warrants, with proceeds allocated to advance clinical and preclinical development, commercial readiness, and general corporate purposes. This capital raise is part of Dianthus's ongoing strategy to fund late-stage autoimmune programs through equity offerings.
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company, has announced the closing of an upsized underwritten public offering, raising approximately $719 million. This includes the full exercise of the underwriters' option to purchase additional shares. The company intends to use the net proceeds to advance clinical and preclinical development, support commercial readiness, and for general corporate purposes.
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Dianthus Therapeutics, Inc. announced the closing of its upsized $719 million underwritten public offering. The offering included the full exercise of the underwriters' option to purchase additional shares and pre-funded warrants. The company plans to use the net proceeds to advance clinical and preclinical development, commercial readiness, and for general corporate purposes.
Dianthus Therapeutics Launches $81-Per-Share Offering; Net Proceeds Expected at $673.5 Million
Dianthus Therapeutics has announced a public offering of 7,313,582 common shares at $81.00 per share and pre-funded warrants for 402,468 shares at $80.999. Underwriters fully exercised an option to purchase an additional 1,157,407 shares. The company anticipates net proceeds of approximately $673.5 million, with the closing expected on March 12, 2026.
Q1 EPS Estimate for Dianthus Therapeutics Reduced by Analyst
HC Wainwright has lowered its Q1 2026 EPS estimate for Dianthus Therapeutics (NASDAQ:DNTH) to ($1.51) from ($0.92), following the company's reported ($1.43) EPS, which missed the consensus of ($0.97). Despite this, analysts largely maintain a "Moderate Buy" rating with an average target of $115.33, propelled by positive clinical trial advancements and recent price target increases from several firms. The company recently completed a significant $625M financing round, which while dilutive, de-risks its development programs.
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing
This SEC filing (Form 144) for Dianthus Therapeutics, Inc. (DNTH) details a proposed sale of 122,918 shares of common stock with an aggregate market value of $10,551,281.12. The securities were acquired on March 12, 2026, through the exercise of stock options, and the sale is planned for approximately March 12, 2026, via Morgan Stanley Smith Barney LLC on NASDAQ. The filing indicates a "Neutral" filing impact and sentiment.
Biotech Dianthus prices $625M deal to advance autoimmune drugs
Dianthus Therapeutics (Nasdaq: DNTH) has priced an upsized underwritten public offering, raising approximately $625 million in gross proceeds. The offering includes 7,313,582 common shares at $81.00 per share and pre-funded warrants for 402,468 shares at $80.999. The net proceeds will be used to advance the company's clinical and preclinical development activities, commercial readiness, and for general corporate purposes, with the offering expected to close on March 12, 2026.
